Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

High-risk HPV prevalence in the Czech cervical cancer screening population: a comparison of clinician-collected and self-collected sampling

H. Jaworek, O. Bouska, P. Kourilova, M. Hajduch, V. Koudelakova

. 2025 ; 35 (4) : 760-765. [pub] 20250801

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25022241

Grantová podpora
IGA LF UP 2025_006 Internal Grant Agency of Palacky University
2025_006 Agency of Palacky University
LX22NPO5102 National Institute for Cancer Research
European Union
Next Generation EU
LM2023053 EATRIS-CZ
Cancer Research Czech Republic

UNLABELLED: The prevalence of high-risk human papillomavirus (hrHPV) types varies across countries, making it essential to estimate prevalence using nationwide samples. Data on hrHPV prevalence in the Czech Republic are very limited. This study aimed to determine the prevalence of various hrHPV types in an unselected screening population of Czech women aged 30-65 years, using paired clinician-obtained cervical swab (CS) and self-collected cervicovaginal swabs (CVS). A total of 1026 eligible women were recruited into two study arms. In arm A, the digene® HC2 DNA Collection Device was used for both CS and CVS. In arm B, the Evalyn Brush was used for CVS, while the Cervex Brush was used for CS. All samples were tested for hrHPV using the digene® HC2 High-Risk HPV DNA Test and genotyped with the PapilloCheck® HPV-Screening assay. The overall hrHPV prevalence was 14.8%, based on positive results from either CVS or CS samples. hrHPV positivity was detected in 10.8% of clinician-obtained CSs and 11.8% of self-collected CVSs. A combined analysis of CS and CVS samples identified the five most prevalent hrHPV genotypes: HPV16, HPV31, HPV39, HPV56, and HPV68. The comparison of hrHPV detection in paired CS and CVS samples showed an overall concordance of 93%. These findings highlight the importance of detecting hrHPV genotypes alongside conventional Pap testing in national cervical screening programs. Furthermore, the results confirm that self-sampling kits represent a suitable alternative to clinician-collected samples. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov Identifier (NCT04133610).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25022241
003      
CZ-PrNML
005      
20251023080158.0
007      
ta
008      
251014s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/eurpub/ckaf045 $2 doi
035    __
$a (PubMed)40194781
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Jaworek, Hana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, The Czech Republic $u Institute of Molecular and Translational Medicine, University Hospital, Olomouc, The Czech Republic
245    10
$a High-risk HPV prevalence in the Czech cervical cancer screening population: a comparison of clinician-collected and self-collected sampling / $c H. Jaworek, O. Bouska, P. Kourilova, M. Hajduch, V. Koudelakova
520    9_
$a UNLABELLED: The prevalence of high-risk human papillomavirus (hrHPV) types varies across countries, making it essential to estimate prevalence using nationwide samples. Data on hrHPV prevalence in the Czech Republic are very limited. This study aimed to determine the prevalence of various hrHPV types in an unselected screening population of Czech women aged 30-65 years, using paired clinician-obtained cervical swab (CS) and self-collected cervicovaginal swabs (CVS). A total of 1026 eligible women were recruited into two study arms. In arm A, the digene® HC2 DNA Collection Device was used for both CS and CVS. In arm B, the Evalyn Brush was used for CVS, while the Cervex Brush was used for CS. All samples were tested for hrHPV using the digene® HC2 High-Risk HPV DNA Test and genotyped with the PapilloCheck® HPV-Screening assay. The overall hrHPV prevalence was 14.8%, based on positive results from either CVS or CS samples. hrHPV positivity was detected in 10.8% of clinician-obtained CSs and 11.8% of self-collected CVSs. A combined analysis of CS and CVS samples identified the five most prevalent hrHPV genotypes: HPV16, HPV31, HPV39, HPV56, and HPV68. The comparison of hrHPV detection in paired CS and CVS samples showed an overall concordance of 93%. These findings highlight the importance of detecting hrHPV genotypes alongside conventional Pap testing in national cervical screening programs. Furthermore, the results confirm that self-sampling kits represent a suitable alternative to clinician-collected samples. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov Identifier (NCT04133610).
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    12
$a časná detekce nádoru $x metody $7 D055088
650    _2
$a plošný screening $x metody $7 D008403
650    12
$a Papillomaviridae $x izolace a purifikace $x genetika $7 D027383
650    12
$a infekce papilomavirem $x epidemiologie $x diagnóza $7 D030361
650    _2
$a prevalence $7 D015995
650    12
$a odběr biologického vzorku $x metody $7 D013048
650    12
$a nádory děložního čípku $x diagnóza $x virologie $x epidemiologie $7 D002583
650    _2
$a vaginální stěr $x metody $7 D014626
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Bouska, Ondrej $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, The Czech Republic
700    1_
$a Kourilova, Pavla $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, The Czech Republic
700    1_
$a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, The Czech Republic $u Institute of Molecular and Translational Medicine, University Hospital, Olomouc, The Czech Republic $u Cancer Research Czech Republic, Olomouc, The Czech Republic
700    1_
$a Koudelakova, Vladimira $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, The Czech Republic $u Institute of Molecular and Translational Medicine, University Hospital, Olomouc, The Czech Republic $1 https://orcid.org/0000000158427478
773    0_
$w MED00012099 $t European journal of public health $x 1464-360X $g Roč. 35, č. 4 (2025), s. 760-765
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40194781 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20251014 $b ABA008
991    __
$a 20251023080203 $b ABA008
999    __
$a ok $b bmc $g 2417200 $s 1260404
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 35 $c 4 $d 760-765 $e 20250801 $i 1464-360X $m European journal of public health $n Eur J Public Health $x MED00012099
GRA    __
$a IGA LF UP 2025_006 $p Internal Grant Agency of Palacky University
GRA    __
$a 2025_006 $p Agency of Palacky University
GRA    __
$a LX22NPO5102 $p National Institute for Cancer Research
GRA    __
$p European Union
GRA    __
$p Next Generation EU
GRA    __
$a LM2023053 $p EATRIS-CZ
GRA    __
$p Cancer Research Czech Republic
LZP    __
$a Pubmed-20251014

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...